Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 2/20 | 0.41 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7670989 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1MC4RSLC1A5TAAR1 | |
| SCHEMBL7666925 | 0.88 | CACNA1B (0.41) | ALDH1A1MC4RCACNA1BANPEPCTSK | |
| SCHEMBL7666920 | 0.88 | CACNA1B (0.41) | ALDH1A1MC4RCACNA1BANPEPCTSK | |
| SCHEMBL7665262 | 0.87 | SLC7A5 (0.45) | KDM4EALDH1A1CACNA1BCTSK | |
| SCHEMBL7665272 | 0.87 | SLC7A5 (0.45) | KDM4EALDH1A1CACNA1BCTSK | |
| SCHEMBL7659977 | 0.81 | CTSK (0.62) | CTSK | |
| SCHEMBL7660322 | 0.78 | CTSK (0.43) | MEN1KMT2AANPEPCTSK | |
| SCHEMBL7664549 | 0.77 | DPP8 (0.44) | ALDH1A1CACNA1BTDP1IDO1 | |
| SCHEMBL7664543 | 0.77 | DPP8 (0.44) | ALDH1A1CACNA1BTDP1IDO1 | |
| SCHEMBL7671477 | 0.74 | DPP4 (0.35) | CACNA1BCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082426-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-27 | — | — | US | disclosed |
| EP-1086083-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1086083-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064399-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082426-A1 | Protease inhibitors | CTSK, CTSZ, CTSB | KDM4E 2200/4885ALDH1A1 2251/4885MC4R 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.